Generic Name: Sacubitril 49mg + Valsartan 51mg
Company Name: GENERAL Pharmaceuticals Ltd.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Indications
This combination is recommended for patients with chronic heart failure (NYHA Class II-IV) and a decreased ejection fraction to reduce the risk of cardiovascular mortality and hospitalization for heart failure.
This combination is typically used in conjunction with other heart failure treatments instead of an ACE inhibitor or other ARB.
Pharmacology
LBQ657, a sacubitril active metabolite, inhibits enkephalinase, a neutral endopeptidase that normally cleaves natriuretic peptides such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and c-type natriuretic peptide (CNP) (CNP). Under atrial and ventricular pressure, ANP and BNP are released to activate posterior receptors, resulting in vasodilation, natriuresis, and diuresis. Enkephalinase normally degrades other vasodilator and vasoconstrictor peptides like angiotensin I and II, endothelin 1, and amyloid-peptide. As a result, neprilysin inhibition reduces the degradation and concentration of endogenous natriuretic peptides while increasing the level of vasoconstrictor hormones such as angiotensin II. (However, when combined with valsartan, it inhibits angiotensin II and its receptors, preventing vasoconstriction and lowering vascular resistance and blood pressure.)
Sacubitril's effects on the cardiovascular system and the kidneys are caused by the usual peptides degraded by enkephalinase.
Valsartan is an oral medication that belongs to the angiotensin receptor blocker class of drugs (ARB). It is an angiotensin II antagonist that acts specifically on the AT1 subtype. Angiotensin binding to its receptors causes blood vessels to constrict (vasoconstriction), resulting in increased blood pressure (hypertension). Valsartan works by blocking angiotensin II receptors. Valsartan dilates blood vessels and lowers blood pressure by blocking the effects of angiotensin without affecting pulse rate. Valsartan has a much higher affinity for the AT1 receptor than the AT2 receptor (about 20,000 times). It does not bind to or block other known hormone receptors or ion channels involved in cardiovascular regulation.
Dosage & Administration
The recommended starting dose of this combination is 49/51 mg twice daily.
Double the dose of this combination after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.
Dose Adjustment For Patients Not Taking An ACE inhibitor Or ARB Or Previously Taking Low Doses Of These Agents.
For patients who are not currently taking an ACE inhibitor or an angiotensin II receptor blocker (ARB) and have previously taken low doses of these agents, a starting dose of 24/26 mg twice daily is recommended. Every 2 to 4 weeks, double the dose of this combination to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.
When combined with an angiotensin-converting enzyme (ACE) inhibitor, sacubitril, and valsartan are contraindicated. Allow a 36-hour washout period between administrations of Sacubitril and Valsartan if switching from an ACE inhibitor.
Contraindications
Contraindications apply to this combination:
Side Effects
Pregnancy & Lactation
Pregnancy: Inform patients of reproductive potential about the consequences of exposure to this combination during pregnancy. Discuss treatment options with women planning to become pregnant. Patients are required to report their pregnancy to the doctor as soon as possible.
Lactation period: There is no information on the presence of sacubitril/valsartan in human milk, its effect on nursing infants, or its effect on milk production. Sacubitril/valsartan is present in rat milk. Because exposure to sacubitril/valsartan may cause serious adverse reactions in breastfed infants, it is recommended that breastfeeding women do not recommend breastfeeding during treatment with sacubitril/valsartan.
Precaution & Warning
Storage Conditions
Store at room temperature between 20°C to 25°C. Protect from moisture.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.